MedTrace Logo

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

NCT04276532 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 780

Last updated 2026-05-12

No results posted yet for this study

Summary

Aim To investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.

Conditions

  • Middle-high Risk Endometrial Cancer
  • Sentinel Lymph Node Sampling
  • Prognosis

Interventions

PROCEDURE

sentinel lymph node sampling (SLN)

Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN). 1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines； 2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted； 3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted.

PROCEDURE

pelvic lymphonodectomy (PLN)

Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with or without para-aortic sampling

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • West China Second University Hospital

    collaborator OTHER

  • Sun Yat-Sen University Cancer Center

    collaborator OTHER

  • Chongqing University Cancer Hospital

    collaborator OTHER

  • Xiaojun Chen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-13
Primary Completion
2027-01-26
Completion
2030-02-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04276532 on ClinicalTrials.gov